➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Harvard Business School
Baxter
Dow
AstraZeneca

Last Updated: June 17, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019627


Email this page to a colleague

« Back to Dashboard

NDA 019627 describes DIPRIVAN, which is a drug marketed by Fresenius Kabi Usa and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the DIPRIVAN profile page.

The generic ingredient in DIPRIVAN is propofol. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the propofol profile page.
Summary for 019627
Tradename:DIPRIVAN
Applicant:Fresenius Kabi Usa
Ingredient:propofol
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 019627
Physiological EffectGeneral Anesthesia
Medical Subject Heading (MeSH) Categories for 019627
Suppliers and Packaging for NDA: 019627
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DIPRIVAN propofol INJECTABLE;INJECTION 019627 NDA Fresenius Kabi USA, LLC 63323-269 63323-269-59 20 VIAL in 1 BOX (63323-269-59) > 50 mL in 1 VIAL
DIPRIVAN propofol INJECTABLE;INJECTION 019627 NDA Fresenius Kabi USA, LLC 63323-269 63323-269-69 10 VIAL in 1 BOX (63323-269-69) > 100 mL in 1 VIAL
Paragraph IV (Patent) Challenges for 019627
Tradename Dosage Ingredient NDA Submissiondate
DIPRIVAN INJECTABLE;INJECTION propofol 019627

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength10MG/ML
Approval Date:Oct 2, 1989TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength10MG/ML
Approval Date:Jun 11, 1996TE:ABRLD:Yes
Patent:  Get Started FreePatent Expiration:Jun 1, 2025Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 019627

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-002 Jun 11, 1996   Get Started Free   Get Started Free
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-002 Jun 11, 1996   Get Started Free   Get Started Free
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-002 Jun 11, 1996   Get Started Free   Get Started Free
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-002 Jun 11, 1996   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Express Scripts
Medtronic
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.